skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Temozolomide in malignant glioma

Review

(2501) Views  (836) Full article downloads

Authors: Gregor Dresemann

Published Date July 2010 Volume 2010:3 Pages 139 - 146
DOI: http://dx.doi.org/10.2147/OTT.S5480

Gregor Dresemann

Center for Neurooncology at Aerztehaus Velen, Velen, Germany

Abstract: Glioblastoma multiforme WHO grade IV (GBM) is the most aggressive ­malignant glioma and the most frequent primary tumor of the central nervous system. The median ­survival of newly diagnosed GBM patients was between 9 to 12 months prior to treatment with ­temozolomide being introduced. Primary resection that is as complete as possible is recommended for malignant glioma. Conventional fractionated irradiation 55 to 60 gy with concomitant temozolomide followed by standard temozolomide 6 cycles (5/28) (EORTC/NCIC-regime published by R Stupp in 2005) is the standard of care for newly diagnosed GBM after surgery, independent of the methylation status of the MGM-T gene promoter. Age is no ­contraindication for treatment with temozolomide, although comorbidity and performance status have to be ­considered. For temozolomide naive GBM and astrocytoma grade III patients with disease progression, temozolomide is still the treatment of choice outside of clinical studies. A ­general consensus regarding the schedule of choice has not yet been achieved; so far the 5 out of 28 days regimen (5/28) is the standard of care in most countries. Patients with disease progression after standard temozolomide (5/28) are candidates for clinical studies. Outside of clinical ­studies, dose-dense (7/7), prolonged (21/28), or metronomic (28/28) temozolomide, or alternatively a nitrosourea-based regimen can be an option. The excellent toxicity profile of ­temozolomide allows for various combinations with antitumor agents. None of these ­combinations, however, have been demonstrated to be statistically significantly superior compared to temozolomide alone. The role of lower dosed, dose-dense, or continuous regimen with or without drug combination and the role of temozolomide for newly diagnosed astrocytoma grade III and low grade glioma still has to be determined.

Keywords: glioblastoma multiforme, astrocytoma WHO grade III, malignant glioma, temozolomide







Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
CTLA-4 blockade: therapeutic potential in cancer treatments
New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab
Update on options for treatment of metastatic castration-resistant prostate cancer
Colonic polyps: inheritance, susceptibility, risk evaluation, and diagnostic management
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Erratum
Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature